Average Insider

Where insiders trade, we follow

$ANTX
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Healthcare
Sector
Biotechnology
Industry
Eric E. Easom
CEO
22
Employees
$2.97
Current Price
$29.05M
Market Cap
52W Low$1.00
Current$2.9733.3% above low, 66.7% below high
52W High$6.91

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00---
Sells00--
1 monthBuys00---
Sells00--
2 monthsBuys00--All Sells
Sells11$346.62327
3 monthsBuys00--All Sells
Sells11$346.62327
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Mar 3, 2026
Williams Sarah Joanne
Principal Accounting Officer
Sale327$1.06$346.62View Details
17 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
Apr 1, 2026
EPS
Estimated-$0.24
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Mar 24, 2026
EPS
Estimated-$0.24
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Mar 17, 2026
EPS
Estimated-$0.24
Actual-$0.29
Miss
Revenue
EstimatedN/A
ActualN/A
3 more earnings records available โ€” create a free account to see 12 months of history
Version: v26.3.33